NCT07373847

Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

A Single-center, Randomized, Placebo-controlled Trial Study to Compare Efficacy, Safety and Tolerability of Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The aim is to evaluate the safety and efficacy of vunakizumab combined with recaticimab versus vunakizumab combined with placebo in the treatment of plaque psoriasis with dyslipidemia.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	vunakizumab and recaticimab.	Adult patients (\>18 years) with moderate-to-severe psoriasis who will start treatment with either vunakizumab and recaticimab.
DRUG	vunakizumab and placebo	Adult patients (\>18 years) with moderate-to-severe psoriasis who will start treatment with either vunakizumab and placebo.

Timeline

• Start date: 2026-01-20
• Primary completion: 2027-06-30
• Completion: 2027-08-30
• First posted: 2026-01-28
• Last updated: 2026-01-28